Peter Neupert - Laboratory Lead Independent Director
LH Stock | USD 218.46 1.89 0.87% |
Director
Mr. Peter M. Neupert is Independent Director of the Company. Mr. Neupert was an Operating Partner at Health Evolution Partners, a health only, middle market private equity firm, from January 2012 until June 2015. Prior to that, Mr. Neupert served as Corporationrationrate Vice President of the Microsoft Health Solutions Group from its formation in 2005 to January 2012. Mr. Neupert served on the Presidents Information Technology Advisory Committee, cochairing the Health Information Technology Subcommittee and helping to drive the Revolutionizing Health Care Through Information Technology report, published in June 2004. Mr. Neupert served as the founding President and Chief Executive Officer of drugstore.com from 1998 to 2001 and as Chairman of the board of directors through September 2004. Mr. Neupert is also a Director of Clinithink Ltd, Adaptive Biotechnologies, Inc., Navigating Cancer Inc., and higi SH Holdings Inc. He served on the Board of Directors of Quality Systems, Inc., now known as NextGen Healthcare, Inc. from August 2013 to January 2014 and Freedom Innovations LLC from May 2013 to April 2016. He serves as a trustee for the Fred Hutchinson Cancer Research Center and was an active member of the Institute of Medicines Roundtable on Value ScienceDriven Healthcare from 2007 to 2011. Mr. Neupert brings to the Board experience as a recognized expert in health information technology and perspective on how to grow shareholder value leveraging business strategies with technology. Mr. Neupert is an audit committee financial expert as a result of his experience, including his experience as CEO and Chairman of drugstore.com. since 2019.
Age | 65 |
Tenure | 5 years |
Address | 358 South Main Street, Burlington, NC, United States, 27215 |
Phone | 336 229 1127 |
Web | https://www.labcorp.com |
Laboratory Management Efficiency
The company has Return on Asset (ROA) of 0.0377 % which means that for every $100 of assets, it generated a profit of $0.0377. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.0423 %, which means that it produced $0.0423 on every 100 dollars invested by current stockholders. Laboratory's management efficiency ratios could be used to measure how well Laboratory manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Capital Employed is estimated to decrease to 0.08. The current Return On Assets is estimated to decrease to 0.02. As of now, Laboratory's Total Current Assets are increasing as compared to previous years. The Laboratory's current Other Assets is estimated to increase to about 531.7 M, while Non Currrent Assets Other are projected to decrease to under 270.8 M.Similar Executives
Showing other executives | DIRECTOR Age | ||
Efrat Venkert | Medigus Ltd ADR | 46 | |
Yair Rabinowitch | Medigus Ltd ADR | 71 | |
Anat Naschitz | Medigus Ltd ADR | N/A | |
Yoav Waizer | Microbot Medical | 51 | |
Alfred Lim | EUDA Health Holdings | 72 | |
Ramona Sequeira | Edwards Lifesciences Corp | 55 | |
Oded Yatzkan | Medigus Ltd ADR | 49 | |
Kieran Gallahue | Edwards Lifesciences Corp | 57 | |
Prattipati Laxminarain | Microbot Medical | 59 | |
Jeremy Starkweather | Medigus Ltd ADR | 42 | |
Solomon Mayer | Microbot Medical | 62 | |
John Cardis | Edwards Lifesciences Corp | 73 | |
Scott Burell | Microbot Medical | 52 | |
Erez Haimovitz | Medigus Ltd ADR | N/A | |
Doron Birger | Medigus Ltd ADR | 66 | |
Yoseph Bornstein | Microbot Medical | 65 | |
Nicholas Valeriani | Edwards Lifesciences Corp | 64 | |
Paul LaViolette | Edwards Lifesciences Corp | 63 | |
Leslie Heisz | Edwards Lifesciences Corp | 60 | |
Eitan Machover | Medigus Ltd ADR | 55 | |
Steven Loranger | Edwards Lifesciences Corp | 69 |
Management Performance
Return On Equity | 0.0423 | ||||
Return On Asset | 0.0377 |
Laboratory Leadership Team
Elected by the shareholders, the Laboratory's board of directors comprises two types of representatives: Laboratory inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Laboratory. The board's role is to monitor Laboratory's management team and ensure that shareholders' interests are well served. Laboratory's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Laboratory's outside directors are responsible for providing unbiased perspectives on the board's policies.
William Klitgaard, President- Enlighten Health | ||
Paul Surdez, IR Contact Officer | ||
Glenn Eisenberg, Chief Financial Officer, Executive Vice President | ||
Deborah Tanner, CEO - Covance Drug Development (Covance) | ||
Stephen Anderson, Vice President Investor Relations | ||
Lance Berberian, Executive Vice President, Chief Technology Officer, Chief Information Officer | ||
Judith Seltz, Chief Human Resource Officer, Executive Vice President | ||
Michelle Abelson, Laboratory Operations | ||
Sanders Williams, Independent Director | ||
John Ratliff, Chief Executive Officer - Covance Drug Development | ||
Kerrii Anderson, Independent Director | ||
JD MD, President EVP | ||
Amy Summy, Executive Vice President Chief Marketing Officer | ||
Mark Schroeder, Executive Vice President and Presidentident of Diagnostics Laboratory Operations and Global Supply Chain | ||
Peter Wilkinson, Senior Vice President, Chief Accounting Officer | ||
Paul MD, Ex Devel | ||
Marcia Eisenberg, Chief VP | ||
Lisa Uthgenannt, Chief Human Resource Officer, Senior Vice President | ||
Brian Caveney, Executive Vice President, President, Diagnostics and Chief Medical Officer | ||
D Gilliland, Independent Director | ||
Gary Huff, CEO, LabCorp Diagnostics | ||
JeanLuc Belingard, Independent Director | ||
Clarissa Willett, IR Contact Officer | ||
Kathryn Wengel, Independent Director | ||
Peter Neupert, Lead Independent Director | ||
Paul Kirchgraber, Executive Vice President and Chief Executive Officer - Covance Drug Development | ||
James Boyle, Executive VP and CEO of Labcorp Diagnostics | ||
Richelle Parham, Independent Director | ||
Robert Williams, Independent Director | ||
Jeffrey Davis, Independent Director | ||
Christin ODonnell, Vice Relations | ||
Chas Cook, VP Relations | ||
Garheng Kong, Independent Director | ||
Gary Gilliland, Independent Director | ||
David King, Chairman of the Board, President, Chief Executive Officer | ||
Adam Schechter, Chairman of the Board, President, Chief Executive Officer | ||
Mark Brecher, Senior Vice President Chief Medical Officer | ||
Samuel Eberts, Senior Vice President Chief Compliance Officer, Secretary, Chief Legal Officer | ||
Sandra Vaart, Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary | ||
Edward Dodson, Chief Accounting Officer and Sr. VP | ||
Scott Frommer, Vice President - Investor Relations | ||
Robert Mittelstaedt, Lead Independent Director | ||
MPH MD, Pres VP |
Laboratory Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Laboratory a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0423 | ||||
Return On Asset | 0.0377 | ||||
Profit Margin | 0.03 % | ||||
Operating Margin | 0.07 % | ||||
Current Valuation | 23.37 B | ||||
Shares Outstanding | 84.1 M | ||||
Shares Owned By Insiders | 0.25 % | ||||
Shares Owned By Institutions | 98.37 % | ||||
Number Of Shares Shorted | 2.13 M | ||||
Price To Earning | 12.69 X |
Laboratory Investors Sentiment
The influence of Laboratory's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Laboratory. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Laboratory's public news can be used to forecast risks associated with an investment in Laboratory. The trend in average sentiment can be used to explain how an investor holding Laboratory can time the market purely based on public headlines and social activities around Laboratory. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Laboratory's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Laboratory's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Laboratory's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Laboratory.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Laboratory in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Laboratory's short interest history, or implied volatility extrapolated from Laboratory options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Laboratory. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. For more detail on how to invest in Laboratory Stock please use our How to Invest in Laboratory guide.Note that the Laboratory information on this page should be used as a complementary analysis to other Laboratory's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Complementary Tools for Laboratory Stock analysis
When running Laboratory's price analysis, check to measure Laboratory's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Laboratory is operating at the current time. Most of Laboratory's value examination focuses on studying past and present price action to predict the probability of Laboratory's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Laboratory's price. Additionally, you may evaluate how the addition of Laboratory to your portfolios can decrease your overall portfolio volatility.
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Transaction History View history of all your transactions and understand their impact on performance | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data |
Is Laboratory's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Laboratory. If investors know Laboratory will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Laboratory listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.46) | Dividend Share 2.88 | Earnings Share 4.33 | Revenue Per Share 139.628 | Quarterly Revenue Growth 0.035 |
The market value of Laboratory is measured differently than its book value, which is the value of Laboratory that is recorded on the company's balance sheet. Investors also form their own opinion of Laboratory's value that differs from its market value or its book value, called intrinsic value, which is Laboratory's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Laboratory's market value can be influenced by many factors that don't directly affect Laboratory's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Laboratory's value and its price as these two are different measures arrived at by different means. Investors typically determine if Laboratory is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Laboratory's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.